Arcus Biosciences Inc
NYSE:RCUS 3:59:58 PM EDT
Earnings Announcements
Arcus Biosciences Posts Quarterly Net Loss Per Share, Basic And Diluted $0.96
Published: 05/09/2022 21:29 GMT
Arcus Biosciences Inc (RCUS) - Arcus Biosciences Reports First Quarter 2022 Financial Results and Provides a Pipeline Update, Including From the Third Interim Analysis for the Arc-7 Study.
Cash, Cash Equivalents and Investments Were $1,342.4 Million As of March 31, 2022.
Expects Cash, Cash Equivalents and Marketable Securities On-hand to Be Sufficient to Fund Operations Into 2026.
Qtrly Net Loss per Share, Basic and Diluted $0.96.
Q1 Earnings per Share View $-0.86 -- Refinitiv Ibes Data (analyst estimates).
Cash, Cash Equivalents and Investments Were $1,342.4 Million As of March 31, 2022.
Expects Cash, Cash Equivalents and Marketable Securities On-hand to Be Sufficient to Fund Operations Into 2026.
Qtrly Net Loss per Share, Basic and Diluted $0.96.
Q1 Earnings per Share View $-0.86 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $21.57 Million
Adjusted EPS is expected to be -$0.94
Next Quarter Revenue Guidance is expected to be $21.86 Million
Next Quarter EPS Guidance is expected to be -$1.02
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.94
Next Quarter Revenue Guidance is expected to be $21.86 Million
Next Quarter EPS Guidance is expected to be -$1.02
More details on our Analysts Page.